EP0876818B1 - Wirkstoff zur behandlung neurodegenerativer störungen - Google Patents
Wirkstoff zur behandlung neurodegenerativer störungen Download PDFInfo
- Publication number
- EP0876818B1 EP0876818B1 EP96935637A EP96935637A EP0876818B1 EP 0876818 B1 EP0876818 B1 EP 0876818B1 EP 96935637 A EP96935637 A EP 96935637A EP 96935637 A EP96935637 A EP 96935637A EP 0876818 B1 EP0876818 B1 EP 0876818B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- weeks
- patients
- pyrido
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention pertains to the use of chemical compounds in medicine, more specifically, to the use of the compounds selected from hydrogenated pyrido[4,3-b]indoles for the treatment of neurodegenerative diseases, and especially Alzheimer's disease (AD), due to the discovery of new properties intrinsic to these compounds.
- chemical compounds selected from hydrogenated pyrido[4,3-b]indoles for the treatment of neurodegenerative diseases, and especially Alzheimer's disease (AD), due to the discovery of new properties intrinsic to these compounds.
- AD Alzheimer's disease
- tacrine hydrochloride which is 9-amino-1,2,3,4-tetrahydroacridine hydrochloride represented by the formula (A):
- the mechanism of action of the said agent involves inhibiting choline esterase (Volger B.W. "Alternatives in the treatment of memory loss in patient with Alzheimer's disease. (Clinical Pharmacy. 1991 June 10 (6): 447 - 56).
- tacrine is an analogue of the world famous physostigmine and is a traditional anticholine esterase agent
- the treatment with tacrine is not always effective. Besides, tacrine tends to cause undesirable side-effects.
- EAA neuromediatory excitatory amino acids
- NMDA N-methyl-D-aspartate
- ⁇ -amyloid is a neurotoxic factor inducing neurodegenerative processes in the neurones.
- ⁇ -Amyloid is present in the neurotic plaques abundantly located on the surface of the brain of the patients suffering from Alzheimer's disease (Prelli et al., - J.Neurochem., 1988, v.51, p.648; Yanuer et al., - Science, 1990, v.250, p.279).
- ⁇ -amyloid significantly enhances the excitotoxic effect of glutamate which is effected through the NMDA-receptor system (Koh et al., Brain Res., 1990, v.533, p.315; Mattson et al., - J. Neurosci., 1992, v. 12, p.376).
- glutamate mediator concentrations nontoxic under normal conditions become toxic for neurones under conditions of the developing ⁇ -amyloid dose and cause their death.
- the search for effective antagonists of the brain NMDA-receptors capable of preventing the realization of the neurotoxic effect of EAA appears to be an original and promising approach to creation of neuroprotectors of a wide spectrum of activity including agents which can prevent the development of Alzheimer's disease and be useful for treatment of such diseases as Alzheimer's disease (Maragos W.F. et al., Trends Neurosci.,1987, No. 10, p.65).
- a well known NMDA receptor antagonist is 2-amino-5-phosphonovaleric acid (AP5) (Evans et al., Brit. J. Pharmacol., 1982, v.75, p.65).
- AP5 2-amino-5-phosphonovaleric acid
- An intensive search for and trials of the agents having the anti-NMDA properties is currently under way for treatment of said disease. However, such agents are actually not available in clinics thus far.
- the object of the invention is to provide compounds having a high anti-NMDA activity and producing no side- and toxic effects.
- the inventors have carried out large-scale investigations of some known compounds which are tetra - and hexahydro-1H-pyrido[4,3-b]indole derivatives manifesting a wide spectrum of biological activity.
- antihistamine activity OS-DE NN 1.813 229, December 6, 1968; 1.952.80, October 20, 1969
- central depressive and antiinflammatory activity USP No.3 718.657 December 13, 1970
- neuroleptic activity Herbert C.A., Plattner S.S., Wehch W.N. - Mol.Pharm.
- hevotroline (8-fluoro-2)(3-(3-pyridyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride) is an antipsychotic and anxiolytic agent (Abou - Gharbi M., Patel U.R., Webb M.B., Moyer J.A., Ardnee T.H., J. Med. Chem., 1987, vol.30, p.1818-1823).
- the inventors have quite unexpectedly found that such properties are endowed for hydrogenated pyrido[4,3-b]indole derivatives. It has been found in particular, that a number of known hydrogenated pyrido[3,4-b]indole derivatives has NMDA antagonist properties, which makes them useful for treating neurodegenerative diseases, especially Alzheimer's disease.
- the present invention relates to the use of a hydrogenated pyrido[4,3-b]indole derivative of formula (I); wherein either;
- mice were treated with white non-inbred male mice of 20 - 24 g weight.
- a solution of the test agent in 0.2 ml of 5% aqueous dimethylsulfoxide was injected intraperitoneally 40 minutes before the injection of NMDA into the lateral vehicle of the brain.
- Mice had been prepared beforehand for the experiment: a skin flap on the head was removed under ether anestesia and a hole was bored in the skull by a fine drill.
- 0.1 ⁇ g of NMDA in a volume of 1.4 ⁇ l was injected with a microsyringe.
- the microsyringe needle was immersed to a depth of 2.5 mm.
- the wound was treated with a 2% novocaine solution.
- the mice showed signs of pain disturbance.
- the accuracy of NMDA injection was monitored by injection of methylene blue. Two to 4 hours after the operation, the mice were used for a pharmacological experiment.
- the animals inoculated with a saline solution were used as control.
- the injection of NMDA into the lateral ventricle in a dose of 0.1 ⁇ g per mouse caused run, jumps, convulsions and then the death of the animals.
- the preinjection of the test substances prevented the development of convulsions and death of the animals.
- the ED 50 value (the dose of the agent preventing the development of convulsions and the death of 50% of the animals) was determined by a probit-analysis method (Litchfild J.T., Wicoxon F.J. - Pharmacol.Exp.Therap., 1949, v. 96. p. 99-114).
- the compounds according to the invention have an anti-NMDA activity expressed as ED 50 in the range of 16 - 45 mg/kg by intraperitoneal inoculation, i.e. in the pharmacologically acceptable range, and do not show any appreciable neurotoxic effect in the investigated doses.
- the marked NMDA-antagonist properties found in the compounds of formula (I) permit a conclusion on the potential usefulness of the said compounds in the treatment of neurodegenerative diseases, and in particular, Alzheimer's disease.
- the “dimebon” agent (compound No.10) which is used in medicine as an antiallergic agent (Inventor's Certificate No. 1138164, IP Class A61K 31/47,5, C07 D 209/52, published on February 7, 1985) was also clinically tested as an agent for treatment of Alzheimer's disease.
- the carbidine agent (compound No.4) is less suitable for preliminary clinical tests due to its obvious psychotropic effect capable of masking some manifestations of positive treatment results. Dimebon is non-toxic and does not show any negative side-effects.
- the test was carried out under the direct supervision by two of the inventors, namely E.E. Bukatina and V.Grigorieva in 14 patients who agreed to take part in the tests, 13 of whom lived in boarding house for senile persons and one patient lived with her family.
- Alzheimer's disease was diagnosed on the basis of criteria ICD-10 NINCDS ADRDA.
- Alzheimer's disease which had started before the admission to the boarding house.
- progressive decline of memory was noted in the boarding house almost 2 years after her admission.
- CT computer tomography
- Dimebon in the form of tablets (comprising 10 mg of dimebon, 30 mg of lactose, 5 mg of magnesium stearate was prescribed for oral administration in a dose of 0.02 g three times a day.
- the patients living in the boarding house received dimebon for 58 days.
- the 0 score indicates the poorest result; on the contrary, according to the inventors' scale, the 0 score indicates the absence of a symptom 4 score indicates the greatest manifestation thereof.
- the degree of disturbance of some function proved to be between the two evaluation indices, the value was of intermediate type, e.g. 0.5, 1.5, or the like.
- the patients had been independently examined by two doctors who used the inventors' scale. The examination during the treatment was carried out by the doctors using both the scales.
- the evaluation according to all the inventors' scale points during all the tests and their variations during the treatment with dimebon are given in the Appendix.
- the degree of the disturbance if the cognitive functions was determined by a sum of evaluations according to the first 5 scale points reflecting the condition of memory, orientation and relation with the reality.
- the disturbance of speech was dealt with separately and was determined by a sum of evaluations according to items 6b-6d. No disturbances of articulation (item 6a) corresponding to peculiar disturbances of speech functions in Alzheimer's disease were observed in any cases.
- test results reflected the condition of the patients a the time of the examination. Any changes in the metal state observed in the interval between the tests and disappearing by the moment of examination according to the scale described in the section "Clinical Observations".
- the statistical data processing was carried out by means of Student's t-test and Fisher's "Fi” criterion.
- Table 3 The test results of 7 patients with relatively mild dementia are presented in Table 3. This group included the patients whose evaluation for each of the inventor's 5-point scale did not exceed 2.5 scores. In fact, only one of the patients had such score (observation 2) according to the 3rd scale point (memory for the past). All the other patients had lower scores.
- Table 10 show some trend for improvement of speech functions during the period of dimebon administration, which was slightly more evident in the prolonged treatment.
- the distribution pattern of the variations in items 6b-6d reflecting the condition of the speech functions is presented in Table 12.
- Psychopathic-like symptoms in all 7 patients who suffered from them decreased significantly during the first 2 weeks or therapy. A distinct antidepressive effect of the agent was also observed in 8 patients. One of them (observation 10) showed no lower spirits during the test period, but, as the medical stuff reported, she had frequent disphorias which ceased during dimebon administration. Besides, the patient herself (dementia was not profound in this case) constantly emphasized that her mood improved during the treatment.
- a pilot research of the effectiveness of dimebon in 14 patients suffering from Alzheimer's disease revealed definite positive effect of the agent on psychopatic-like and depressive manifestations.
- the examinations carried out using Hazegawa's scale and the inventors scale revealed a significant improvement in cognitive functions especially in patients with mild dementia.
Claims (11)
- Verwendung eines hydrierten Pyrido[4,3-b]indolderivates der Formel (I) worinLinie ----- eine Einfachbindung bedeutet undR1 Me bedeutet, R2 H bedeutet und R3 Me bedeutet und die Verbindung in der Form eines cis (±)-Isomers vorliegt, oder die Linie ----- eine Doppelbindung bedeutet und(i) R1 Et oder PhCH2 bedeutet und R2 und R3 H bedeuten,(ii) R1 und R2 Me bedeuten und R2 PhCH2 bedeutert,(iii) R1 Me bedeutet, R2 6-Me-3-Py-(CH2)2 bedeutet und R3 H bedeutet,(iv) R1 und R3 Me bedeuten und R2 6-Me-3-Py-(CH2)2 bedeutet,(v) R1 Me bedeutet, R2 H bedeutet und R3 H oder Me bedeutet,(vi) R1 Me bedeutet, R2 H bedeutet und R3 Br bedeutet,
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2-Methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol oder dessen Methyljodid ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) cis-(±) 2,8-Dimethyl-2,3,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indol oder dessen Dihydrochlorid ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2-Methyl-8-brom-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol oder dessen Hydrochlorid ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (1) 2-Ethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2,8-Dimethyl-5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol oder dessen Hydrochlorid ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2-Methyl-5-[2-(6-methyl-3-pyridyl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol oder dessen Sesquisulfatmonohydrat ist.
- Verwendung nach Anspruch 1, worin das Derivat der Formel (I) 2,8-Dimethyl-5-[2-(6-methyl-3-pyridyl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol oder dessen Dihydrochlorid ist.
- Verwendung nach einem der vorausgehenden Ansprüche, wobei das Derivat der Formel (I) ein quaternäres Salz ist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9630572T SI0876818T1 (en) | 1995-10-23 | 1996-10-23 | Agent for treating neuro-degenerative disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU95118252A RU2106864C1 (ru) | 1995-10-23 | 1995-10-23 | Средство для лечения болезни альцгеймера |
RU95118252 | 1995-10-23 | ||
PCT/RU1996/000306 WO1997015225A1 (fr) | 1995-10-23 | 1996-10-23 | Agent therapeutique contre les troubles neurodegeneratifs |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0876818A2 EP0876818A2 (de) | 1998-11-11 |
EP0876818A4 EP0876818A4 (de) | 1999-01-07 |
EP0876818B1 true EP0876818B1 (de) | 2002-12-18 |
Family
ID=20173218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96935637A Expired - Lifetime EP0876818B1 (de) | 1995-10-23 | 1996-10-23 | Wirkstoff zur behandlung neurodegenerativer störungen |
Country Status (11)
Country | Link |
---|---|
US (6) | US6187785B1 (de) |
EP (1) | EP0876818B1 (de) |
AT (1) | ATE229806T1 (de) |
AU (1) | AU7347496A (de) |
CA (1) | CA2269698C (de) |
DE (1) | DE69625518T2 (de) |
DK (1) | DK0876818T3 (de) |
ES (1) | ES2188793T3 (de) |
HK (1) | HK1016893A1 (de) |
RU (1) | RU2106864C1 (de) |
WO (1) | WO1997015225A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012016707A2 (en) | 2010-08-06 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form for the modified release of dimebolin |
WO2012016708A1 (en) | 2010-08-06 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form comprising dimebolin and donepezil |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
CA2363244C (en) * | 2000-11-07 | 2006-06-13 | Research In Motion Limited | Multifunctional keyboard for a mobile communication device and method of operating the same |
WO2004035580A1 (en) * | 2002-10-21 | 2004-04-29 | Aprea Ab | Reactivation of wild type p53 in human tumour cells by a low molecular weight compound |
RU2283108C2 (ru) * | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
US20070179174A1 (en) * | 2003-12-08 | 2007-08-02 | Bachurin Sergei O | Methods and compositions for slowing aging |
FR2885905A1 (fr) * | 2005-05-23 | 2006-11-24 | Trophos Sa | Nouveaux composes chimiques et leurs utilisations comme medicament |
WO2007032699A1 (fr) * | 2005-09-12 | 2007-03-22 | Avdulov, Nikolai Andreevich | Isomeres optiques (+) et (-) de trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pirido[4,3-b]indole |
US20070117834A1 (en) * | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
RU2317989C1 (ru) | 2006-08-24 | 2008-02-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
AU2007297618A1 (en) * | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine Cognitive Dysfunction Syndrome |
US20100099700A1 (en) * | 2006-09-20 | 2010-04-22 | David Hung | Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als) |
WO2008051599A2 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
RU2329044C1 (ru) * | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
RU2334514C1 (ru) * | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
RU2340342C2 (ru) * | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
WO2008112238A1 (en) * | 2007-03-12 | 2008-09-18 | Grey Fox Llc | 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain |
RU2334747C1 (ru) * | 2007-04-05 | 2008-09-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
RU2327480C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом |
RU2338533C1 (ru) * | 2007-06-28 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
EP2194980A4 (de) * | 2007-09-20 | 2012-01-18 | D2E Llc | Fluor-haltige derivate von hydrogenierten pyrido[4,3-b]indolen mit neuroprotektiven und kognitionsverbessernden eigenschaften, herstellungsverfahren und verwendung |
RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
TWI447117B (zh) * | 2007-10-25 | 2014-08-01 | Medivation Technologies Inc | 新穎四環化合物 |
JP2011507835A (ja) * | 2007-12-21 | 2011-03-10 | アンドレイ・アレクサンドロビッチ・イワシェンコ | α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用 |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
CN102046625B (zh) | 2008-03-24 | 2015-04-08 | 梅迪维新技术公司 | 桥连杂环化合物及其使用方法 |
BRPI0906244A2 (pt) * | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit |
EP2272955B1 (de) * | 2008-04-09 | 2015-08-26 | Tokyo Metropolitan Institute of Medical Science | Tdp-43-speicherzellmodell |
RU2374245C1 (ru) * | 2008-08-22 | 2009-11-27 | Андрей Александрович Иващенко | Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство |
EP2340254B8 (de) | 2008-09-15 | 2014-05-21 | Biovista, Inc. | Zusammensetzungen und verfahren zur behandlung von epilepsie |
US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
EP2344505A2 (de) | 2008-09-29 | 2011-07-20 | Abbott Laboratories | Indol- und indolinderivate sowie verwendungsverfahren dafür |
BRPI0919948A2 (pt) | 2008-10-31 | 2015-08-25 | Madivation Technologies Inc | Pirido[4,3-b]indois contendo porções rígidas |
US8569287B2 (en) | 2008-10-31 | 2013-10-29 | Medivation Technologies, Inc. | Azepino[4,5-B]indoles and methods of use |
US20100137215A1 (en) * | 2008-11-25 | 2010-06-03 | Concert Pharmaceuticals Inc. | Novel tetrahydro-1h-pyrido[4,3-b]indoles |
CN107595841A (zh) | 2009-01-09 | 2018-01-19 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP2396327A1 (de) | 2009-02-11 | 2011-12-21 | Sunovion Pharmaceuticals Inc. | Inverse histamin-h3-agonisten und -antagonisten und verfahren zu ihrer verwendung |
EP2236160A3 (de) | 2009-03-31 | 2011-12-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dimebolin enthaltende Zusammensetzungen mit modifizierter Freisetzung |
EP2236159A3 (de) | 2009-03-31 | 2011-12-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dimebolin enthaltende Zusammensetzungen mit modifizierter Freisetzung |
TR200903014A1 (tr) | 2009-04-17 | 2010-11-22 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Oral yolla dağılan dimebolin bileşimleri. |
CA2760516A1 (en) | 2009-04-29 | 2011-02-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
US9255094B2 (en) | 2009-04-29 | 2016-02-09 | Medivation Technologies, Inc. | Pyrido[4,3-B]indoles and methods of use |
EP2480081A4 (de) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | Gebrückte heterocyclische verbindungen und verfahren zu ihrer verwendung |
EP2480078A4 (de) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | Pyrido-[4,3-b-]indole und verwendungsverfahren dafür |
CN102724875B (zh) | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚化合物及其使用方法 |
WO2011039675A2 (en) | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine transdermal therapeutic dosage forms |
WO2011039686A1 (en) | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Latrepirdine oral sustained release dosage forms |
WO2011039670A1 (en) | 2009-09-30 | 2011-04-07 | Pfizer Inc. | Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole) |
RU2428185C1 (ru) * | 2009-12-29 | 2011-09-10 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ ГИДРИРОВАННОГО ПИРИДО(4,3-b)ИНДОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ |
TR201001117A1 (tr) | 2010-02-15 | 2011-09-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Dimebolin ve memantin kombinasyonları |
US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
RU2451686C1 (ru) * | 2010-12-27 | 2012-05-27 | Александр Васильевич Иващенко | ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
AU2012254158B2 (en) | 2011-02-18 | 2016-02-04 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
DE102012003065A1 (de) * | 2012-02-13 | 2013-08-14 | Friedrich-Schiller-Universität Jena | Neue bivalente Gammacarbolinderivate sowie deren Herstellung und Verwendung als Antidementiva |
WO2013130422A1 (en) | 2012-02-27 | 2013-09-06 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
EP2887805A4 (de) * | 2012-08-22 | 2016-08-17 | Medivation Technologies Inc | Verbindungen und verfahren zur behandlung von bluthochdruck |
EP2887803A4 (de) | 2012-08-24 | 2016-08-03 | Univ Texas | Pro-neurogene verbindungen |
WO2014207241A1 (en) * | 2013-06-28 | 2014-12-31 | Alzprotect | NEW Na-SUBSTITUTED CARBOLINE COMPOUNDS USABLE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
EP3068388A4 (de) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Nervenschützende verbindungen und verwendung davon |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
EP2918792A1 (de) * | 2014-03-13 | 2015-09-16 | Siemens Aktiengesellschaft | Dampfkraftanlage mit Spindelleckdampfleitung |
CN109535157B (zh) * | 2018-12-03 | 2021-10-15 | 江苏科技大学 | 一种半蜡梅碱类似物、其合成方法及其用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1138164A1 (ru) * | 1963-04-25 | 1985-02-07 | Shadurskij Konstantin S | Антигистаминное средство "димебон |
DE1813229A1 (de) | 1967-12-08 | 1970-08-20 | Sumitomo Chemical Co | gamma-Carboline und ihre Salze und Verfahren zu ihrer Herstellung |
US3743740A (en) * | 1968-10-31 | 1973-07-03 | I Zhukova | 3,6-dimethyl - 1,2,3,4,4a,9a - hexahydro-ypsilon-carboline dihydrochloride for treating mental diseases |
GB1276113A (en) | 1969-10-17 | 1972-06-01 | Nii Farmakologii I Khim | 3,6-DIMETHYL 1,2,3,4a,9a-HEXAHYDRO-gamma-CARBOLINE DIHYDROCHLORIDE |
DE1952800C3 (de) | 1969-10-20 | 1974-04-18 | Nautschno-Issledowatelskij Institut Farmakologii I Chimioterapii, Moskau | 3,6-Dimethyl-l,2,3,4,4a,9a-hexahydro-gamma-carbolin-dihydrochlorid |
US3718657A (en) * | 1970-12-03 | 1973-02-27 | Abbott Lab | Certain-2-substituted-1,2,3,4-tetrahydro-beta or gamma carbolines |
SE7414572L (de) * | 1973-12-06 | 1975-06-09 | Endo Lab | |
AR205452A1 (es) * | 1973-12-06 | 1976-05-07 | Endo Lab | Metodo para preparar nuevos trans-2, 3, 4, 4a, 5, 9b-hexahidro-5-fenil-1h-pirido(4,3-b) indoles |
US4174453A (en) * | 1973-12-06 | 1979-11-13 | Endo Laboratories, Inc. | Trans-hexahydro-pyrido-indoles |
SE441448B (sv) * | 1977-05-23 | 1985-10-07 | Pfizer | Sett att framstella hexahydro-gamma-karbolinforeningar |
US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
GB8600783D0 (en) | 1986-01-14 | 1986-02-19 | Merck Sharp & Dohme | N-methyl-d-aspartate receptor antagonists |
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US4985256A (en) * | 1988-04-27 | 1991-01-15 | Bionix Corporation | Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory |
US6017957A (en) * | 1989-08-08 | 2000-01-25 | The United States Of America As Represented By The Department Of Health And Human Services | Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
EP0424179A3 (en) | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US5319096A (en) * | 1992-04-03 | 1994-06-07 | Hoechst-Roussel Pharmaceuticals Inc. | (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use |
DE4212529A1 (de) * | 1992-04-10 | 1993-10-14 | Schering Ag | Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten |
US5248690A (en) | 1992-07-07 | 1993-09-28 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US6362160B1 (en) * | 1993-06-30 | 2002-03-26 | The Johns Hopkins University School Of Medicine | Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
RU2140417C1 (ru) | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
US6391871B1 (en) * | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
US5958919A (en) * | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
JP2003517023A (ja) * | 1999-12-16 | 2003-05-20 | バイオジェン インコーポレイテッド | 中枢神経系の虚血性損傷または出血性損傷を、抗α4インテグリンアンタゴニストを用いて処置する方法 |
RU2283108C2 (ru) | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
-
1995
- 1995-10-23 RU RU95118252A patent/RU2106864C1/ru active
-
1996
- 1996-10-23 US US09/269,602 patent/US6187785B1/en not_active Expired - Lifetime
- 1996-10-23 AU AU73474/96A patent/AU7347496A/en not_active Abandoned
- 1996-10-23 WO PCT/RU1996/000306 patent/WO1997015225A1/ru active IP Right Grant
- 1996-10-23 AT AT96935637T patent/ATE229806T1/de active
- 1996-10-23 ES ES96935637T patent/ES2188793T3/es not_active Expired - Lifetime
- 1996-10-23 DK DK96935637T patent/DK0876818T3/da active
- 1996-10-23 EP EP96935637A patent/EP0876818B1/de not_active Expired - Lifetime
- 1996-10-23 CA CA002269698A patent/CA2269698C/en not_active Expired - Fee Related
- 1996-10-23 DE DE69625518T patent/DE69625518T2/de not_active Expired - Lifetime
-
1999
- 1999-05-11 HK HK99102096A patent/HK1016893A1/xx not_active IP Right Cessation
-
2001
- 2001-02-06 US US09/778,662 patent/US20010020028A1/en not_active Abandoned
-
2002
- 2002-01-23 US US10/057,688 patent/US20020115682A1/en not_active Abandoned
-
2003
- 2003-08-28 US US10/652,435 patent/US20040044022A1/en not_active Abandoned
-
2004
- 2004-12-02 US US11/004,001 patent/US7071206B2/en not_active Expired - Fee Related
-
2006
- 2006-02-24 US US11/361,628 patent/US20060140866A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012016707A2 (en) | 2010-08-06 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form for the modified release of dimebolin |
WO2012016708A1 (en) | 2010-08-06 | 2012-02-09 | Ratiopharm Gmbh | Oral dosage form comprising dimebolin and donepezil |
Also Published As
Publication number | Publication date |
---|---|
HK1016893A1 (en) | 1999-11-12 |
US20020115682A1 (en) | 2002-08-22 |
US7071206B2 (en) | 2006-07-04 |
DE69625518D1 (de) | 2003-01-30 |
US20040044022A1 (en) | 2004-03-04 |
US20060140866A1 (en) | 2006-06-29 |
CA2269698A1 (en) | 1997-05-01 |
WO1997015225A1 (fr) | 1997-05-01 |
RU2106864C1 (ru) | 1998-03-20 |
US6187785B1 (en) | 2001-02-13 |
US20050096342A1 (en) | 2005-05-05 |
AU7347496A (en) | 1997-05-15 |
DE69625518T2 (de) | 2003-09-04 |
EP0876818A2 (de) | 1998-11-11 |
CA2269698C (en) | 2007-09-18 |
US20010020028A1 (en) | 2001-09-06 |
EP0876818A4 (de) | 1999-01-07 |
ES2188793T3 (es) | 2003-07-01 |
ATE229806T1 (de) | 2003-01-15 |
DK0876818T3 (da) | 2003-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0876818B1 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
US11426419B2 (en) | Compositions and methods for the repair of myelin | |
CN101987849B (zh) | 治疗与年龄相关的黄斑变性(amd)的方法 | |
JP2010507672A (ja) | アルツハイマー病を治療するための方法および組み合わせ治療 | |
US5693645A (en) | Use of spiperone or spiperone derivatives as immunosuppressant agents | |
US20020048612A1 (en) | GABA substrate and the use thereof for treating cognitive and emotional disorders | |
US5510381A (en) | Method of treatment of mania and bipolar disorder | |
AU2004233587A1 (en) | Use of a topical medicament comprising Riluzole | |
JP2021507945A (ja) | 認知症を含む神経障害のための組成物および治療方法 | |
JP2021507944A (ja) | 運動ニューロン疾患を含む神経障害のための組成物および治療方法 | |
US20230129151A1 (en) | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders | |
JPH08510990A (ja) | グリシンnmdaレセプター複合体の機能的アンタゴニストによる認識の改良方法 | |
JPH0354922B2 (de) | ||
US5484788A (en) | Buspirone as a systemic immunosuppressant | |
JP2006516629A (ja) | 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法 | |
JPH0813741B2 (ja) | 抗痴呆剤 | |
CN101293831B (zh) | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 | |
JPH1179995A (ja) | 多発性硬化症治療剤 | |
US20110224300A1 (en) | USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA | |
JPH05502446A (ja) | 老人性痴呆症治療のためのグリシル―p―アミノ―ピリジン | |
Kamath | Study of Anticonvulsant effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model In Albino Mice | |
JP2003221337A (ja) | 酢酸アミド誘導体を有効成分とする痴呆症治療剤 | |
JPH0541603B2 (de) | ||
JPH06505255A (ja) | 皮膚病治療薬の調製へのテトラヒドロ−チエノピリドインドール誘導体の使用 | |
JP2017155007A (ja) | 自閉スペクトラム症改善用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980525 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 980525;LV PAYMENT 980525;RO PAYMENT 980525;SI PAYMENT 980525 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19981119 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20001221 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/475 A, 7A 61P 25/28 B |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/475 A, 7A 61P 25/28 B |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/475 A, 7A 61P 25/28 B |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SELENA PHARMACEUTICALS, INC |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SELENA PHARMACEUTICALS, INC |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19980525;LV PAYMENT 19980525;RO PAYMENT 19980525;SI PAYMENT 19980525 |
|
REF | Corresponds to: |
Ref document number: 229806 Country of ref document: AT Date of ref document: 20030115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
RIN2 | Information on inventor provided after grant (corrected) |
Free format text: ZEFIROV, NIKOLAI SERAFIMOVICH * AFANASIEV, ANDREI ZAKHAROVICH * AFANASIEVA, SVETLANA VASILIEVNA * BACHURIN, SERGEI OLEGOVICH * TKACHENKO, SERGEI EVGENIEVICH * GRIGORIEV, VLADIMIR VIKTOROVICH * JUROVSKAYA, MARINA ABRAMOVNA * CHETVERIKOV, VALERY PAVLOVICH * BUKATINA, ELIZAVETA EVGENIEVNA * GRIGORIEVA, IRINA VLADIMIROVNA |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69625518 Country of ref document: DE Date of ref document: 20030130 Kind code of ref document: P Ref document number: 69625518 Country of ref document: DE Date of ref document: 20030130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030400914 Country of ref document: GR |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20021218 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2188793 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030919 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: MEDIVATION, INC. Free format text: SELENA PHARMACEUTICALS, INC#167 SKYVIEW WAY#SAN FRANCISCO, CALIFORNIA 94131 (US) -TRANSFER TO- MEDIVATION, INC.#501 SECOND STREET, SUITE 211#SAN FRANCISCO, CA 94107 (US) |
|
NLS | Nl: assignments of ep-patents |
Owner name: MEDIVATION, INC. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: MEDIVATION, INC. US Effective date: 20040625 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: IF |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: MEDIVATION NEROLOGY, INC, US Effective date: 20080808 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: MEDIVATION NEUROLOGY, INC. Free format text: MEDIVATION, INC.#201 SPEAR STREET, 3RD FLOOR#SAN FRANCISCO, CALIFORNIE 94105 (US) -TRANSFER TO- MEDIVATION NEUROLOGY, INC.#201 SPEAR STREET, 3RD FLOOR#SAN FRANCISCO, CA 94105 (US) Ref country code: CH Ref legal event code: PCOW Free format text: MEDIVATION, INC.;201 SPEAR STREET, 3RD FLOOR;SAN FRANCISCO, CALIFORNIE 94105 (US) |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: SP73 Owner name: MEDIVATION NEUROLOGY, INC.; US Effective date: 20090702 |
|
NLS | Nl: assignments of ep-patents |
Owner name: MEDIVATION NEUROLOGY, INC. Effective date: 20090616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20130927 Year of fee payment: 18 Ref country code: DK Payment date: 20130925 Year of fee payment: 18 Ref country code: PT Payment date: 20130423 Year of fee payment: 18 Ref country code: MC Payment date: 20130927 Year of fee payment: 18 Ref country code: IE Payment date: 20130926 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20130925 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20131105 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130924 Year of fee payment: 18 Ref country code: CH Payment date: 20131029 Year of fee payment: 18 Ref country code: AT Payment date: 20130925 Year of fee payment: 18 Ref country code: DE Payment date: 20131031 Year of fee payment: 18 Ref country code: SE Payment date: 20131007 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20131016 Year of fee payment: 18 Ref country code: NL Payment date: 20131010 Year of fee payment: 18 Ref country code: BE Payment date: 20131104 Year of fee payment: 18 Ref country code: FI Payment date: 20131007 Year of fee payment: 18 Ref country code: ES Payment date: 20131011 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20150423 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69625518 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20150501 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20141031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 229806 Country of ref document: AT Kind code of ref document: T Effective date: 20141023 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20141023 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20030400914 Country of ref document: GR Effective date: 20150505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141024 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150423 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150501 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150630 Ref country code: SI Ref legal event code: KO00 Effective date: 20150610 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150501 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150505 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141023 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141031 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20151127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141024 |